tetano
Editor, Senior Moderator
Transl Res
. 2021 Nov 18;S1931-5244(21)00280-2.
doi: 10.1016/j.trsl.2021.11.007. Online ahead of print.
Advances in mRNA and other vaccines against MERS-CoV
Wanbo Tai[SUP] 1 [/SUP], Xiujuan Zhang[SUP] 1 [/SUP], Yang Yang[SUP] 2 [/SUP], Jiang Zhu[SUP] 3 [/SUP], Lanying Du[SUP] 4 [/SUP]
Affiliations
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and SARS-CoV-2, MERS-CoV has a significantly higher fatality rate with limited human-to-human transmissibility. MERS-CoV causes sporadic outbreaks, but no vaccines have yet been approved for use in humans, thus calling for continued efforts to develop effective vaccines against this important CoV. Similar to SARS-CoV-1 and SARS-CoV-2, MERS-CoV contains four structural proteins, among which the surface spike (S) protein has been used as a core component in the majority of currently developed MERS-CoV vaccines. Here, we illustrate the importance of the MERS-CoV S protein as a key vaccine target and provide an update on the currently developed MERS-CoV vaccines, including those based on DNAs, proteins, virus-like particles or nanoparticles, and viral vectors. Additionally, we describe approaches for designing MERS-CoV mRNA vaccines and explore the role and importance of naturally occurring pseudo-nucleosides in the design of effective MERS-CoV mRNA vaccines. This review also provides useful insights into designing and evaluating mRNA vaccines against other viral pathogens.
Keywords: Coronavirus; MERS-CoV; mRNA; spike protein; vaccines.
. 2021 Nov 18;S1931-5244(21)00280-2.
doi: 10.1016/j.trsl.2021.11.007. Online ahead of print.
Advances in mRNA and other vaccines against MERS-CoV
Wanbo Tai[SUP] 1 [/SUP], Xiujuan Zhang[SUP] 1 [/SUP], Yang Yang[SUP] 2 [/SUP], Jiang Zhu[SUP] 3 [/SUP], Lanying Du[SUP] 4 [/SUP]
Affiliations
- PMID: 34801748
- DOI: 10.1016/j.trsl.2021.11.007
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and SARS-CoV-2, MERS-CoV has a significantly higher fatality rate with limited human-to-human transmissibility. MERS-CoV causes sporadic outbreaks, but no vaccines have yet been approved for use in humans, thus calling for continued efforts to develop effective vaccines against this important CoV. Similar to SARS-CoV-1 and SARS-CoV-2, MERS-CoV contains four structural proteins, among which the surface spike (S) protein has been used as a core component in the majority of currently developed MERS-CoV vaccines. Here, we illustrate the importance of the MERS-CoV S protein as a key vaccine target and provide an update on the currently developed MERS-CoV vaccines, including those based on DNAs, proteins, virus-like particles or nanoparticles, and viral vectors. Additionally, we describe approaches for designing MERS-CoV mRNA vaccines and explore the role and importance of naturally occurring pseudo-nucleosides in the design of effective MERS-CoV mRNA vaccines. This review also provides useful insights into designing and evaluating mRNA vaccines against other viral pathogens.
Keywords: Coronavirus; MERS-CoV; mRNA; spike protein; vaccines.